$OCUL News

Acuta Capital Sells 56% of Ocular Therapeutix Shares in Q1

What This Fund’s $14 Million Ocular Therapeutix Exit Could Signal for Investors

Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Ocular Therapeutix, Inc. (OCUL) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Ocular Therapeutix Starts SOL-X Trial As AXPAXLI Data And Valuation Diverge

Assessing Ocular Therapeutix (OCUL) Valuation As Axpaxli Expectations Meet Volatile Returns

RBC Capital Reiterates Outperform on Ocular Therapeutix, Maintains $30 Price Target

Ocular Therapeutix Q1 Earnings Call Highlights

Ocular Therapeutix, Inc. (OCUL) Q1 2026 Earnings Call Transcript

Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix Inc (NASDAQ:OCUL) Misses on Revenue and EPS in Q1 2026, Stock Dips

Ocular Therapeutix™ Reports First Quarter 2026 Financial Results and Business Highlights

Ocular Therapeutix Q1 EPS $(0.40) Misses $(0.33) Estimate, Sales $10.785M Miss $12.599M Estimate

Ocular Therapeutix (OCUL) To Report Earnings Tomorrow: Here Is What To Expect

How Investors Are Reacting To Ocular Therapeutix (OCUL) Advancing AXPAXLI Toward NDA After Positive SOL-1 Trial

How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL)

Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data

Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMD

Ocular Therapeutix Enrolls First Patient In SOL-X Long-term Extension Trial For Axpaxli (Also Known As OTX-TKI) For Wet Age-related Macular Degeneration

Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026